Opinion/decision on a Paediatric investigation plan (PIP): Rosuvastatin (calcium),fenofibrate, decision type: , therapeutic area: , PIP number: P/0001/2023

Human medicines European public assessment report (EPAR): Skyrizi, risankizumab, Psoriasis;Arthritis, Psoriatic, Date of authorisation: 26/04/2019, Revision: 18, Status: Authorised

Opinion/decision on a Paediatric investigation plan (PIP): Diclofenac (sodium),Thiamine (hydrochloride),pyridoxine (hydrochloride),cyanocobalamin, decision type: , therapeutic area: , PIP number: P/0035/2023

Human medicines European public assessment report (EPAR): Zirabev, bevacizumab, Colorectal Neoplasms;Breast Neoplasms;Carcinoma, Non-Small-Cell Lung;Carcinoma, Renal Cell;Uterine Cervical Neoplasms, Date of authorisation: 14/02/2019, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Lonquex, lipegfilgrastim, Neutropenia, Date of authorisation: 25/07/2013, Revision: 27, Status: Authorised

Guidance on good manufacturing practice and good distribution practice: Questions and answers

Human medicines European public assessment report (EPAR): Velmetia, sitagliptin,metformin, Diabetes Mellitus, Type 2, Date of authorisation: 16/07/2008, Revision: 37, Status: Authorised

Human medicines European public assessment report (EPAR): Oyavas, bevacizumab, Colorectal Neoplasms;Breast Neoplasms;Ovarian Neoplasms;Fallopian Tube Neoplasms;Peritoneal Neoplasms;Carcinoma, Non-Small-Cell Lung;Carcinoma, Renal Cell;Uterine Cervical Neoplasms, Date of authorisation: 26/03/2021, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Talmanco (previously Tadalafil Generics), tadalafil, Hypertension, Pulmonary, Date of authorisation: 09/01/2017, Revision: 8, Status: Authorised

Opinion/decision on a Paediatric investigation plan (PIP): Bis-choline tetrathiomolybdate, decision type: , therapeutic area: , PIP number: P/0164/2022